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OBJECTIVES: Anti-tumor necrosis factor (TNF)-α agents like Infliximab (IFX) are effective in the treatment of inflammatory bowel
diseases (IBDs) and are widely used. However, a considerable number of patients do not respond or lose response to this therapy.
Preliminary evidence suggests that transmembrane TNF-α (tmTNF-α) might be linked to response to IFX by promoting reverse
signaling-induced apoptosis in inflammatory cells. The main aim of this study was the evaluation of this hypothesis in primary IFX
non-responders.
METHODS: A total of 47 IFX naive IBD patients were included in the study. Blood samples were taken before the start of IFX therapy
(at week 0) and after induction therapy (at week 14). Endoscopic disease activity and markers of inflammation at baseline and at
week 14 were used to evaluate response. Baseline soluble TNF-α (sTNF-α), percentage of circulating TNF-α positive cells, mean
fluorescence intensity (MFI) of tmTNF-α, and apoptosis rate at week 14 in the peripheral blood mononuclear cells (PBMCs) were
evaluated in IFX responders and non-responders.
RESULTS: Mean sTNF-α was not significantly different in responders compared to non-responders (P= 0.13). Mean percentage of
tmTNF-α bearing lymphocytes and monocytes was higher in the PBMCs of responders (P= 0.05 and P= 0.014, respectively).
Mean MFI of tmTNF-α in circulating lymphocytes and monocytes was greater in responders (P= 0.002 and Po0.001, respectively).
Moreover, the mean percentage of apoptosis in PBMCs was significantly greater in responders compared to non-responders
(P= 0.002).
CONCLUSIONS: The percentage of tmTNF-α bearing lymphocytes and monocytes and the intensity of tmTNF-α in the circulating
leukocyte population of IBD patients was directly related to primary response to IFX. This was likely due—as assessed by the
apoptosis rate—to promotion of inflammatory cell death. Thus, our data suggest that peripheral leukocytes could in principle be
used for predicting primary response to IFX in IBD patients.
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INTRODUCTION
Inflammatory bowel disease (IBD)—primarily, Crohn’s disease
(CD) and ulcerative colitis (UC)1—are quickly becoming a
global healthcare problem2 as patients are becoming refrac-
tory to the most effective medications, the anti-tumor necrosis
factor-α (anti-TNF-α) agents.3 Elevated levels of pro-
inflammatory cytokines have been demonstrated in serum
and intestinal mucosa of IBD patients. Among them, TNF-α
appears to be a key player.4 Inhibition of TNF-α bymonoclonal
antibodies—such as Infliximab (IFX) and Adalimumab—has
been shown for more than a decade to be the most effective
treatment for IBD patients; however, despite their proven
efficacy, up to 30% of biological naive patients do not respond
to anti-TNF agents after the induction phase—so-called
primary non response (PNR)—and up to 13% per year of
those who initially respond will eventually lose response over
time (secondary loss of response (SLR)).3,5,6 The mechan-
isms at the basis of PNR and SLR might be multiple and are
still not fully understood. The literature suggests that PNRmay
be associated with stricturing disease and lack of response to
anymedical therapy.5,6 In primary non-responders the disease
could also be driven by a biological process (partially)
independent of TNF-α. Alternatively, the drug dose might
simply not be enough for the patient’s effective disease
burden.7,8 Finally, the lack of response could be due to other
less clear factors (genetics, drug metabolism and disposi-
tion).5 Unfortunately, in clinical practice it is often difficult to
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identify the mechanism at the basis of PNR and SLR, and to
accurately predict therapeutic response to anti-TNF agents
from the outset. Clearly, the identification of biomarkers
capable of predicting such response remains an important
goal in clinical IBD research today.
Transmembrane TNF-α (tmTNF-α), a precursor of the
soluble form of TNF-alpha (sTNF-α), is expressed on activated
macrophages and lymphocytes as well as other cell types.
After processing by TNF-α converting enzyme, the sTNF-α is
cleaved from tmTNF-α and mediates its biological activities
through binding to TNF receptors of remote tissues. Accumu-
lating evidence suggests that not only sTNF-α but also tmTNF-
α is involved in the inflammatory response. tmTNF-α acts as a
bipolar molecule that transmits signals both as a ligand and as
a receptor. On TNF-α-producing cells it binds to TNF
receptors, and transmits signals to the target cell as a ligand,
while also acting as a receptor transmitting outside-to-inside
signals back to the cell.9–11 When playing the receptor role,
tmTNF-α also acts as a receptor for IFX. Binding of IFX to
tmTNF-α activates several anti-inflammatory mechanisms
including 'tmTNF-α reverse signaling-induced apoptosis',
which is considered one of the most important.11–13 In this
process, tmTNF-α acts as a cell surface receptor binding the
circulating IFX and thereby activating apoptosis of the
tmTNF-α bearing inflammatory cells. Apoptosis with depletion
of the inflammatory cells will then result in attenuation of
inflammation.
Thus, the concentration of tmTNF-α and the number of
tmTNF-α bearing cells might be related to IFX response in IBD.
A greater tmTNF-α density could lead to more effective
induction of IFX-induced apoptosis in inflammatory cells, and
to a better clinical response to IFX. Were that the case, the
density of tmTNF-α and the number of tmTNF-α bearing cells
could be leveraged as biomarkers of IFX response. In this
study we have tested such hypotheses in patients with PNR
to IFX.
METHODS
Patients. IFX naive IBD patients, who failed corticosteroids
and/or immunomodulators, were included in the study. The
inclusion criteria were as follows: verifiable diagnosis of CD or
UC based on standard endoscopic, radiologic, and histologic
criteria;14–16 age 16 years or older; testing negative for
hepatitis B and C; human immunodeficiency virus; latent or
current tuberculosis (by chest X-ray and tuberculin skin test);
serum cytomegalovirus PCR; and negative stool Clostridium
difficile and stool culture. Exclusion criteria were as follows:
previous IBD-related intestinal resection, perianal disease,
history of severe heart disease, neurodegenerative diseases,
pregnancy, and previous history of colon cancer. In addition,
patients were excluded in the presence of intestinal strictures,
abscess, fistulas, or sepsis—conditions that might impact on
medical response to anti-TNF-α agents or any other
medication.5,6 Hence, all the CD patients had a non-
stricturing, non-penetrating phenotype (Montreal B1).17 We
also stipulated that patients demonstrating intolerance to IFX
had to be excluded from the study.
Written informed consent was obtained from all subjects
and the protocol was approved by the local Ethical Committee.
Study protocol. The treatment protocol included a standard
IFX dose of 5 mg/kg at weeks 0, 2, and 6 as induction, and
every 8 weeks thereafter as maintenance. The first blood
sample was drawn at baseline, before the first IFX infusion.
Peripheral blood mononuclear cells (PBMCs) were extracted
and subjected to flow cytometry. The percentage of TNF-α-
positive lymphocytes and monocytes, along with the intensity
of TNF-α expression in each cell population was also
analyzed. Serum samples were analyzed for sTNF-α level.
At week 14, a blood sample was collected immediately
before the 4th IFX infusion. PBMCs were extracted and
subjected to flow cytometric analysis for the evaluation of
apoptosis and additional tests (see below).
Endoscopic assessment was conducted at weeks 0 and 14
(see next paragraph). Figure 1 shows the flowchart of the
study protocol in detail.
Evaluation of response to IFX. The common clinical
definition of PNR to IFX is the lack of improvement of clinical
signs and symptoms with induction therapy.3,5 However, in
our study we chose more objective and reliable parameters of
therapeutic response namely endoscopic disease activity
and markers of inflammation before and after treatment. For
the purpose, colonoscopy was performed at week 0 (base-
line) and 14, immediately before the first maintenance
infusion. Endoscopic response in UC was defined as an
improvement of the endoscopic Mayo score of at least one
point from baseline.18 Endoscopic response in CD was
defined as a decrease of ≥ 5 in the CDEIS score.19 In
Figure 1 Flowchart of the study. ATI, antibodies to infliximab; FC, fecal
calprotectin; IFX, Infliximab; ITL, Infliximab trough level; PBMC, peripheral blood
mononuclear cells; sTNF-α, serum TNF-α; tmTNF-α, transmembrane TNF-α.
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addition, C-reactive protein (CRP), and fecal calprotectin (FC)
(FCal ELISA, Bühlmann, Schönenbuch, Switzerland) were
measured at weeks 0 and 14, using an enzyme-linked
immunosorbent assay (ELISA). A CRP level of (up to) 5 mg/l
and FC level of (up to)100 μg/g were considered normal
values.
Finally, to gain additional knowledge on the mechanism at
the basis of PNR, IFX trough levels (ITL) and antibodies to IFX
(ATI) (IDKmonitor-infliximab drug level ELISA and IDKmonitor-
infliximab total ADA ELISA, Immundiagnostik AG, Bensheim,
Germany) were measured immediately before the 4th IFX
infusion at week 14 by ELISA. An ITL of 0.8 μg/ml and an ATI
value of 10 U/ml were considered as cutoff detection levels.
IDKmonitor-infliximab total ADA ELISA detects total ADA
(bound and free ADA) and is categorized as a drug-
tolerant assay.
Flow cytometric analysis of PBMCs. PBMCs were isolated
by gradient centrifugation on a layer of Ficoll-Paque Plus
(Amersham, Uppsala, Sweden). For the evaluation of tmTNF-
α mean fluorescence intensity (MFI), extracted leukocytes
were subjected to the acid wash process to remove receptor-
bound TNF (cells were reconstituted for 5 min in RPMI 1640
medium, pH 2.5 containing 10% FBS). Cells were then
washed twice with PBS before flow cytometric evaluation.
The cells were stained for tmTNF-α by phycoerythrin
conjugated anti-TNF-α monoclonal antibody (PE-Mouse
Anti-Human TNF, Biolegend, San Diego, CA) in PBS with
1% bovine serum albumin and 0.1% sodium azide for 30 min
at 4 °C. Before staining, cells were Fc-blocked by 1 μg of
human IgG for 15 min at room temperature. Using the gating
strategy, based on forward scatter (FSC) and side scatter
(SSC) two separate gates were identified for the lymphocyte
and monocytes populations (Supplementary Figure 1S).
For the assessment of PBMCs’ apoptotic activity, cells were
stained by FITC Annexin V Apoptosis Detection Kit (BioLe-
gend) with Propidium Iodide. Briefly, the cells were washed
twice with cold BioLegend's Cell Staining Buffer, and then
were re-suspended in Annexin V Binding Buffer. Subse-
quently, FITC Annexin V and Propidium Iodide Solution were
added. Following 15 min incubation at room temperature in the
dark, annexin V Binding Buffer was added. The cellswere then
subjected to flow cytometry.
Staining with the relevant isotype-matched control mono-
clonal antibody (BioLegend) was performed in all flow
cytometric evaluations.
Immediately after staining, flow cytometric analysis was
performed on a FACScalibur flow cytometer (Becton Dick-
inson, Franklin Lakes, NJ). At least 10 000 PBMCs per sample
were analyzed. The data were analyzed using Flow Jo
software (Tree star, Ashland, OR). An example of an individual
run of apoptotic rates in responders and non-responders is
illustrated in Supplementary Figure 2S.
sTNF-α analysis. Collected serum samples were stored at
−80 °C until analysis. Serum levels of TNF-α were measured
by ELISA, according to the protocol provided by the
manufacturer (Human TNF-alpha Quantikine HS ELISA,
R&D Systems-Minneapolis, MN). Human TNF-α controls
(QuantiGlo Immunoassay Control Set 732 for Human TNF-
alpha) were also used to increase the test accuracy.
Statistical analysis. Statistical analysis was performed
using IBM SPSS for Windows, version 21 (IBM Armonk,
NY). Central tendency and variability for numeric variables
were measured using the mean and s.d., respectively.
Normality test was performed for dependent variables. For
normally distributed variables the parametric independent
t-test and the paired t-test were used. For variables which
were not normally distributed, the non-parametric Mann–
Whitney U-test and Wilcoxon test were used. The Pearson/
Spearman’s correlation coefficient was used to test potential
correlation of variables. The analysis of covariance test was
used to analyze mean differences among two groups with
treatment as factor and baseline as covariate. The prognostic
value of candidate variables was evaluated by plotting receiver
operating characteristic curves and calculation of the area
under the curve. Maximum point of the Youden's index
(Youden's J) was identified as the cutoff value in the separation
of responders and non-responders. The Youden's index is the
likelihood of a positive test result in subjects with the condition
vs. those without the condition. This index combines sensitivity
and specificity into a single measure and has a value between
0 and 1. In a perfect test the Youden's value equals 1.
A P value ≤0.05 was considered statistically significant.
RESULTS
Table 1 shows the baseline characteristics of the enrolled
patients. In total, 63 IFX naive IBD patients were identified as
eligible for the study. Of the 63 eligible patients, 16 patients did
not complete the treatment protocol and were later excluded.
In total, 47 IFX naive IBD patients were evaluated in this study
(Figure 1).
The patient population was composed by 22 females and 25
males, with 34 CD and 13 UC patients. The mean age was 36
years, ranging from 17 to 60. The mean duration of disease
was 6.6 years, ranging from 3 to 12. Only 8.5% of patients
Table 1 Baseline characteristics of IBD patients
Variable Results
UC (n= 13) CD (n= 34)
Mean Age (mean± s.d.) years 38.7±14.6 35± 13.8
Gender (Males, %) 53.8 52.9
Positive smoking history (%) 15.4 6
Positive family history of IBD (%) 7.7 20
Mean disease duration (mean± s.d.)
years
6.7±1.7 6.6±2.1
Classification:
L1—ileal (%) — 10 (29.4)
L2—colonic (%) 11 (32.4)
L3—ileocolonic (%) 13 (38.2)
Classification:
E1—rectum (%) 0 —
E2—left sided (%) 5 (38.5)
E3—extensive (%) 8 (61.5)
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were smokers at time of enrollment and 17% had a family
history of IBD. Of the CD patients, equal proportions had ileal,
colonic and ilecolonic disease. Of the UC patients 62% had
pancolitis and 38% left sided colitis.
Based on the endoscopic criteria described in Methods, a
total of 30 responders and 17 non-responders were identified
in our cohort. The clinical and laboratory characteristics of
responders and non-responders are compared in Table 2.
Almost 2/3 ofUCandCDpatientswere primary responders. At
baseline (week 0, before therapy), the CDEIS and Mayo
subscore were similar in the two groups. After induction therapy
(week 14), the mean CDEIS score in CD patients decreased by
8.3 points in responders compared to 1.45 points in
non-responders (Po0.001). In UC patients, the mean
Mayo endoscopic subscore decreased by 1.37 points in
responders, while it increased by 0.2 points in non-responders
(Po0.001).
ITL were 4.1±2.4 in responders compared to 1.1±1.1 μg/
ml (Po0.001) in non-responders. In 57% of responders and
12% of non-responders ITL waswithin the therapeutic window
(3–7 μg/ml).20 ATI were present in 35.3% of non-responders
and in 10% of responders. Mean CRP and FC were similar at
baseline in the two groups. Mean CRP decreased by 17.5% in
non-responders and by 86% in responders after induction
therapy (Po0.001). Mean FC decreased by 75% in respon-
ders after induction therapy, while it increased by 12% in non-
responders (Po0.001).
Next, sTNFa and tm-TNF-αweremeasured at baseline, and
apoptosis at week 14.
Mean sTNF-α was 24.1±41.8 pg/ml vs. 20.6±31.6 pg/ml,
in responders vs. non-responders, respectively (P=0.13)
(Figure 2a).
The mean percentage of tmTNF-α bearing lymphocytes
was borderline statistically different between responders and
non-responders (71.4±13.6 vs. 64.3±12.1, respectively,
P= 0.05) (Figure 2b).The mean percentage of tmTNF-α
bearing monocytes was significantly greater in responders
compared to non-responders (66.5± 9.6 vs. 59.8± 6.5,
respectively, P=0.014) (Figure 2b).
Mean lymphocyte MFI of tmTNF-α was greater in respon-
ders compared to non-responders (34.1±12.1 vs.
18.5±12.6, P=0.002) (Figure 2c). No significant correlation
was observed between the lymphocyte MFI and sTNF-α
values (r=− 0.043, P=0.77). Mean monocyte MFI of
Table 2 Comparison of clinical and laboratory characteristics of IFX responders and nonresponders
Variable Responders Non-responders P value
UC (%) CD (%) UC (%) CD (%)
Disease type 8 (26.7) 22 (73.3) 5 (29.4) 12 (70.6) –
30 (63.8) 17 (36.2) –
CDEIS week 0 – 17.6±4.7 – 18.9± 4.3 0.43
CDEIS week 14 – 9.3±3.4 – 17.4± 4.7 o0.001
Mayo endoscopic subscore week 0 2.6±0.5 – 2.2±0.4 – 0.15
Mayo endoscopic subscore week 14 1.3±0.5 – 2.4±0.5 – 0.002
ITL (μg ml− 1) week 14 5.6±3.6 3.5±1.6 0.9±1.1 1.2± 1.1
4.1± 2.4 1.1±1.1 o0.001
ITL within therapeutic window (3–7 μg ml−1) at week 14 5 (63) 12 (55) 0 (0) 2 (16)
17 (57) 2 (12) o0.001
ITL week 14, ≥ 0.8 μg/ ml− 1 8 (100) 20(91) 3 (60) 6 (50)
28 (93.3) 9 (52.9) 0.002
Negative ATI week 14 8 (100) 19 (86.4) 3 (60) 8 (66.7)
27 (90) 11 (64.7) 0.004
CRP (mg/L) week 0 34.5±47.3 45±43 35.1±29 42± 37
42± 44 40±36 0.75
CRP (mg/L) week 14 5.1±2.5 6.6±4.9 25.5±33 36.6± 33
6±4.5 33±31 0.005
Mean CRP week 14,o5 mg /l− 1 7 (87.5) 16 (72) 4 (80) 4 (33)
23 (76.7) 8 (47.1) 0.04
FC μg/ g− 1 week 0 541.1±444 612±441 477.4±411 594.6± 392
593± 435 560±406 0.86
FC μg/ g− 1 week 14 120.1±91.2 146.1±110 491.8±555 689± 378
139± 107 631±429 o0.001
Mean FC week 14,o100 μg/ g− 1 7 (87.5) 14 (63.6) 1 (20) 0 (0)
21 (70) 1 (5.9) o0.001
Abbreviations: ATI, antibodies to infliximab; CD, Crohn’s disease; CDEIS, Crohn's disease Endoscopic Index of Severity; FC, fecal calprotectin; IFX, infliximab; ITL, IFX
trough level; UC, ulcerative colitis.
Data are shown as N (%) or mean± s.d.
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tmTNF-α was also significantly greater in responders
compared to non-responders (31.3±10.4 vs. 17.1± 9.9,
respectively, Po0.001) (Figure 2c). No significant correlation
was observed between the monocyte MFI and sTNF-α values
(r=− 0.101, P=0.49).
The mean percentage of apoptosis in PBMCs was
significantly greater in responders compared to non-respon-
ders, (4.1±1.3% vs. 2.8±1%, respectively, P= 0.002)
(Figure 2d). A significant positive correlation was observed
between apoptosis and tmTNF-α MFI values of both lympho-
cytes andmonocytes with correlation coefficients of 0.783 and
0.689, respectively (Po0.001). There was no significant
correlation between apoptosis and sTNF-α levels (r=−0.100,
P= 0.5).
Construction of receiver operating characteristic curves and
calculation of area under the curve was used to evaluate the
prognostic power of MFI in tmTNF-α bearing lymphocytes and
monocytes to predict response to IFX.
For the lymphocyte MFI, area under the curve was 0.827
(95% confidence interval, 0.695–0.960; Po0.001) with the
optimal cutoff value of 30.5, with a sensitivity and specificity of
83.3 and 88.2, respectively (Figure 3a).
For the monocytes MFI, area under the curve was 0.884
(95% confidence interval, 0.787–0.982; Po0.001) with an
optimal cutoff value of 24.5, with sensitivity and specificity of
86.7 and 88.2, respectively (Figure 3b).
DISCUSSION
Anti-TNF agents, including IFX, arewidely used inmoderate to
severe IBD. However, a sizeable proportion of biological naive
patients fail to respond (PNR) or lose response over time
Figure 2 sTNF-α, tmTNF-α bearing lymphocytes and monocytes, lymphocyte and monocyte tmTNF-αMFI (measured at baseline), and apoptosis in IFX responders and IFX
non-responders (measured at 14 weeks). (a) Mean sTNF-α level; (b) percentage of tmTNF-α bearing lymphocytes and monocytes; (c) MFI of tmTNF-α in lymphocytes and
monocytes; (d) percentage of apoptosis in PBMCs. IFX, Infliximab; MFI, mean fluorescence intensity; PBMC; sTNF-α, soluble TNF-α; tmTNF-α, transmembrane TNF-α. The
asterisk indicates a statistically significant difference.
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(SLR). Given the potentially serious adverse effects of IFX and
the financial burden it imposes to both health systems and
patients, the identification of biomarkers which could help
predict response to IFX might reduce the risks and costs for
those patients who will fail to respond.21,22
Several potential biomarkers have been proposed to predict
PNR to IFX in IBD patients.22 Among them, the role of serum
TNF-α level in IFX response has been widely investigated.
However, there is no consensus as to its utility.
Martinez-Borra et al. reported that a high serum TNF-α level
is associated with lack of response to IFX in CD patients.23 By
contrast, Magnusson et al. showed that baseline levels of
TNF-α tended to be higher in responders than in non-
responders.24 Others have shown that baseline serum TNF-
α in rheumatoid arthritis patients might provide a good
estimation of the global disease burden and—as such—
should be targeted in IFX dose titration studies.25
In addition to the neutralization of sTNF-α, IFX appears to
attenuate inflammation by the so-called “tmTNF-α reverse
signaling-induced apoptosis” whereby tmTNF-α appears to
act as a cell surface receptor binding circulating IFX, binding
which in turn triggers reverse signaling and other events,
including apoptosis of the tmTNF-α bearing cells, a de facto
cellular suicide.11–13 This mechanism of action of IFX seems
to be clinically very important. In fact, IBD patients do not
respond to Etanercept, (another anti-TNF-α agent) which—by
contrast with IFX—only appears to inhibit sTNF-α, but does
not induce reverse signaling through tmTNF-α binding.4,13,26
In this regard, Atreya et al. showed that CD patients with a
high number of tmTNF-α positive cells (as tested in inflamed
intestinal tissue) had a better response to anti-TNF-α therapy
when compared to patients with a low number of tmTNF-α
positive cells.27
In this study, we tested the hypothesis that a high density of
TNF-α on the surface of TNF-α bearing circulating cells might
lead to more efficient induction of reverse signaling associated
apoptosis, and might predict response to IFX in IBD patients.
For the purpose, we enrolled CD and UC patients naive to IFX
and tested sTNF-α, percentage of circulating TNF-α positive
monocytes and lymphocytes, MFI of tmTNF-α in circulating
lymphocytes and monocytes, and apoptosis rate in PBMCs of
IFX responders and non-responders. It is important to stress
that patients were identified as responders or non-responders
based on a solid objective clinical outcome—endoscopic
activity—after full induction therapy. In addition, we measured
blood and stool markers of inflammation before and after
therapy. We believe that these are more reliable indicators of
response than symptomatic improvement after the IFX
induction phase.3,5 Enrolled patients had no strictures or other
disease complications which would have made them poten-
tially resistant to any medical therapy. We also measured ITL
and ATI—based on the currently held opinion that resistance
to IFX might be due to low ITL or to the presence of ATI, albeit
less likely in PNR than in SLR.5,6
A total of 47 patients completed the study. More than 2/3
responded to IFX, showing a significant drop in endoscopic
scores, CRP and FC levels. IFX responders had higher ITL
when compared to non-responders. In addition, 35% of non-
responders (and 10% of responders) had detectable ATI
levels. It should be noted that the use of a drug-tolerant assay
allowed us to detect ATI in the presence of an adequate IFX
concentration.28 These data (as well as the very restrictive
inclusion criteria) further suggest overall that in our patient
population the lack of response—when present—could be
driven by factors other than immune response to IFX such as a
specific biologic mechanism. Indeed, the MFI value of tmTNF-
Figure 3 ROC curves for lymphocyte (a) and monocyte (b) MFI. MFI, mean fluorescence intensity; ROC, receiver operating characteristic.
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α was significantly lower in IFX non-responders compared to
IFX responders, in both monocytes and lymphocytes. In
addition, the apoptosis rate in PBMCs was also lower in IFX
non-responders compared to IFX responders. By contrast,
sTNF-α did not significantly differ in the two populations and
did not correlate with MFI values and apoptotic rates. Taken
together these findings might suggest that in non-responders
less circulating IFX binds to tmTNF-α which in turn might lead
to faster clearance (leading to lower ITL) and decreased
efficacy.
Other data suggest that PNR might be due to a disease
burden exceeding the neutralizing capacity of the standard
IFX dose.7,8,29 However, our findings are not inconsistent with
such conclusion. They rather suggest that in PNR IFX efficacy
seems to be hampered by a defective target—which could in
principle be overcome by larger medication doses, a scenario
functionally and clinically indistinguishable from a greater
disease burden. Clearly, many other mechanisms might also
be at play.
Similar observations have beenmade in other diseases. For
example, different sensitivity to apoptosis induced by anti-
TNF-α therapy has been previously shown in PBMCs of
rheumatoid arthritis patients.30
Hence, our results show that in principle a simple blood test
in PBMCs could be used to predict response to IFX in IBD
patients. This conclusion is also supported by the good
prognostic value, sensitivity and specificity of tmTNF-α MFI of
both lymphocytes and monocytes as assessed by receiver
operating characteristic and area under the curve.
Potential limitations of our study are the relatively small
sample size and the relatively short follow up. In addition, we
have only studied patients with PNR to IFX—and it is not clear
whether our findings would also apply to SLR.
In conclusion, our data show that the intensity of tmTNF-α
on circulating leukocytes in IBD patients is related to IFX
response in both CD and UC. This observation has the
potential to be used clinically given its relatively low cost and
lack of invasiveness. Further studies to confirm these findings
are warranted.
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Study Highlights
WHAT IS CURRENT KNOWLEDGE
• A considerable number of inflammatory bowel disease (IBD)
patients who start infliximab therapy either do not respond to
the induction therapy or lose response during treatment.
• The identification of biomarkers capable of predicting
response to infliximab is of considerable clinical importance.
• Transmembrane tumor necrosis factor-α (TNF-α) -induced
apoptosis is known as the main mechanism of action that
produces the anti-inflammatory effects of infliximab.
WHAT IS NEW HERE
• Density of transmembrane TNF-α on the circulating immune
cells is different among IBD patients.
• Patients with higher transmembrane TNF-α demonstrate
higher apoptosis level after infliximab therapy.
• Density of transmembrane TNF-α, as a mechanism-based
biomarker, could predict primary response to infliximab.
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